Journal of Surgical Research
Volume 158, Issue 1 , Pages 33-34 , January 2010

Commentary

Received 2 April 2009

References 

  1. Trikalinos TA, Alsheikh-Ali AA, Tatsioni A, et al. Percutaneous coronary interventions for non-acute coronary artery disease: A quantitative 20-year synopsis and a network meta-analysis. Lancet. 2009;373:911
  2. Bavry AA, Bhatt DL. Appropriate use of drug-eluting stents: Balancing the reduction in restenosis with the concern of late thrombosis. Lancet. 2008;371:2134
  3. Gioia G, Benassi A, Mohendra R, et al. Lack of clinical long-term benefit with the use of a drug eluting stent compared to use of a bare metal stent in saphenous vein grafts. Catheter Cardiovasc Intervent. 2008;72:13
  4. Conte MS, Bandyk DF, Clowes AW, et al. PREVENT III Investigators. Results of PREVENT III: A multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J Vasc Surg. 2006;43:742
  5. Alexander JH, Hafley G, Harrington RA, et al. PREVENT IV Investigators. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: A randomized controlled trial. JAMA. 2005;294:2446
  6. Bandyk DF, Schmitt DD, Seabrook GR, et al. Monitoring functional patency of in situ saphenous vein bypasses: The impact of a surveillance protocol and elective revision. J Vasc Surg. 1989;9:286
  7. Tummers AM, Mountain DJH, Mix JW, et al. Serum levels of matrix metalloproteinase-2 as a marker of intimal hyperplasia. J Surg Res 2009 (in press).
  8. McDermott MM, Guralnik JM, Greenland P, et al. Inflammatory and thrombotic blood markers and walking-related disability in men and women with and without peripheral arterial disease. J Am Geriatr Soc. 2004;52:1888
  9. Wilson AM, Kimura E, Harada RK, et al. β2-Microglobulin as a biomarker in peripheral arterial disease: Proteomic profiling and clinical studies. Circulation. 2007;116:1396
  10. Findley CM, Mitchell RG, Duscha BD, et al. Plasma levels of soluble Tie2 and vascular endothelial growth factor distinguish critical limb ischemia from intermittent claudication in patients with peripheral arterial disease. J Am Coll Cardiol. 2008;52:387
  11. Fung ET, Wilson AM, Zhang F, et al. A biomarker panel for peripheral arterial disease. Vasc Med. 2008;13:217

PII: S0022-4804(09)00223-6

doi: 10.1016/j.jss.2009.04.028

Journal of Surgical Research
Volume 158, Issue 1 , Pages 33-34 , January 2010

Article Tools